期刊文献+

华法林抗凝过程中不良反应及其影响因素分析 被引量:12

Adverse reaction in warfarin anticoagulation and influence factors
下载PDF
导出
摘要 华法林(warfarin)是临床上最常用的口服抗凝血药,用于治疗和预防各种血栓栓塞性疾病。华法林治疗窗窄,个体差异大,因而剂量要求各有不同,并且用药不足会达不到抗凝效果,而用药过量又会增加出血风险。华法林相关不良事件中最常见的即为出血反应。本文汇总了近年来关于华法林出血性研究,分析了影响出血的相关因素以及其作用机制,期望能为临床安全使用华法林进行抗凝治疗提供参考。 Warfarin is the most widely used oral anticoagulant in clinical use today. It is used for the prevention and treatment of thromboembolic events in patients. Warfarin has a narrow therapeutic range and widespread interindividual variation, so the dose requirements are different. Dose shortage may not show the anticoagulant effect, but overdose may increase the risk of bleeding, which is the most common adverse events. This review summarizes the recent re- search on wafarin complications, analyzes the influence factors of hemorrhage and its mechanism, and hopes to provide a reference for safe clinical use of wafarin anticoagulant.
出处 《中南药学》 CAS 2015年第10期1058-1061,共4页 Central South Pharmacy
基金 科技部国际科技合作与交流专项(No.2014DFA30900)
关键词 口服抗凝药 华法林 出血反应 影响因素 oral anticoagulant wafarin bleeding complication influence factor
  • 相关文献

参考文献40

  • 1The Boston Area Anticoagulation Trial for Atrial Fibrillation In- vestigators. The effect of low-dose warfarin on the risk of stro- ke in patients with nonrheumatic atrial fibrillation [J]. N Engl J Med, 1990, 323 (22) : 1505-1511.
  • 2Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators [J]. N Engl J Med, 1992, 327 (20) : 1406-1412.
  • 3Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Fo- cused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease [J]. Circulation, 2008, 118 (15) : e523-e661.
  • 4Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic thera- py for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (SthEdition) [J]. Chest, 2008, 133 (4) : 454S-545S.
  • 5Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines ( 8th Edition) [J]. Chest, 2008, 133 ( 6 Suppl) ~ 257S-298S.
  • 6Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation [J]. Ann InternMed, 2004, 141 (10) : 745-752.
  • 7Wysowski DK, Nourjah P, Swartz L, et al. Bleeding complica- tions with warfarin use: a prevalent adverse effect resulting in regu- latoryaction[J].ArchIntemMed, 2007, 167 (13) : 1414-1419.
  • 8Joseph Menzin, Matthew sussMan, Christine Nichols, et al. Use of blood products in patients with anticoagulant-related major bleeding: An analysis of inhospital outcomes [J]. Am J Health-SystPharm, 2014, 71 (19) : 1635-1645.
  • 9Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium ofAnticoagulation Cli- nics [J]. Ann Intern Med, 1996, 124 (11) : 970-979.
  • 10Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation [J]. CMAJ, 2013, 185 (2) : E121-127.

二级参考文献16

共引文献52

同被引文献123

引证文献12

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部